RECOVERED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY AND METHOD OF INHIBITION OF PSMA-EXPRESSING CELL GROWTH Russian patent published in 2011 - IPC C07K16/30 C12P21/08

Abstract RU 2421466 C2

FIELD: medicine.

SUBSTANCE: invention concerns anti-PSMA antibodies which contain variable sites of heavy and light chains; the antibody does not contain fucosyl residues. Amino acid sequences of said chains are presented in the formula. Antibodies under the invention are a monoclonal antibody, a humanised or chimeric antibody, a human antibody. Also, there is described a method of inhibition of PSMA+ cell growth, such as tumour cells by contact of said cells with the anti-PSMA antibodies.

EFFECT: antibodies show higher, antibody-dependent prostate cancer cell cytotoxicity as compared with a fucosyl antibody form.

32 cl, 3 tbl, 6 ex

Similar patents RU2421466C2

Title	Year	Author	Number
ISOLATED ANTI-CD30 ANTIBODY (VERSIONS); HOST CELL, METHOD OF OBTAINING CHIMERIC OR HUMANISED VERSION OF ANTI-CD30 ANTIBODIES (VERSIONS), METHOD OF INHIBITING GROWTH OF CELLS CD30+ AND METHOD OF INHIBITING GROWTH OF TUMOUR CELLS EXPRESSING CD30	2006	Blehk Amelija Nehnsi Kardarelli Dzhozefin M.	RU2492186C2
J591 MINIBODIES AND CYS-DIABODIES FOR TARGETED DELIVERY OF HUMAN PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND METHODS FOR THEIR USE	2010	Kho Devid Olafson Touv Lipman Arie	RU2673908C2
INTERFERON ALPHA 1 RECEPTOR ANTIBODIES AND USE THEREOF	2005	Kardarelli Zhozefin M. Vitte Elison Srinivasan Mokhan	RU2600884C2
ANTIBODIES OF INTERFERON ALFA RECEPTOR 1 AND THEIR APPLICATION	2005	Kardarelli Zhozefin M. Vitte Ehlison Srinivasan Mokhan	RU2412202C2
HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS	2013	Korman Alan Dzh. Srinivasan Mokhan Van Chanyuj Selbi Mark Dzh. Chen Bin Kardarelli Zhozefin M.	RU2599417C2
HUMAN MONOCLONAL ANTIBODIES TO THE PROTEIN OF PROGRAMMED DEATH 1 (PD-1) AND METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS	2016	Korman Alan Dzh. Srinivasan Mokhan Van Chanyuj Selbi Mark Dzh. Chen Bin Kardarelli Zhozefin M.	RU2732924C2
HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR PROGRAMMED CELL DEATH 1 (PD1) PROTEIN AND METHODS OF TREATING CANCER WITH USING ANTI-PD1 ANTIBODIES EITHER INDIVIDUALLY, OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS	2006	Korman Alan Dzh. Srinivasan Mokhan Van Chanjuj Selbi Mark Dzh. Chehn' Bin Kardarelli Zhozefin M. Khuan Khajchun'	RU2494107C2
HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS	2006	Korman Alan Dzh. Srinivasan Mokhan Van Chanjuj Selbi Mark Dzh. Chehn' Bin Kardarelli Zhozefin M.	RU2406760C2
MEDICINAL AGENT CONTAINING PHOSPHOLIPASE D4 ANTIBODY	2014	Yamazaki Tomokhide Endo Mayuki Isida Kodzi	RU2709741C2
MONOCLONAL ANTIBODY TO NAV1.7	2019	Takahashi Tatsuya Yoshikawa Mai Yoneda Sosuke Onoda Junji Nakamura Etsuo Miyauchi Tsuguo Asaki Toshiyuki Kasai Erika	RU2776821C2

RU 2 421 466 C2

Authors

Albaniz Dzhenni

Kardarelli Dzhozefin M.

Pehssmor Dehvid B.

Chzhu Lej

Dates

2011-06-20—Published

2006-02-17—Filed